[Canrenoate potassium in the treatment of hyperosmolar syndromes during resuscitation].
D002056:Burns / Q000150:complications; D002264:Carboxylic Acids / Q000494:pharmacology; D004232:Diuretics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007664:Ketosteroids / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists; D009318:Natriuresis / Q000187:drug effects; D009994:Osmolar Concentration / Q000187:drug effects; D011188:Potassium / Q000652:urine; D011245:Pregnadienes / Q000494:pharmacology*; D012151:Resuscitation; D012769:Shock / Q000188:drug therapy; D014882:Water-Electrolyte Balance / Q000187:drug effects*
D002264:Carboxylic Acids; D004232:Diuretics; D007664:Ketosteroids; D000451:Mineralocorticoid Receptor Antagonists; D011245:Pregnadienes; D011188:Potassium
Il canrenoato di potassio nel trattamento delle sindromi iperosmolali in rianimazione